Bank Of The Ozarks Upped By $625,290 Its Abbott Labs (ABT) Stake; ZARDOYA OTIS ORDINARY SHARES (ZRDZF) Shorts Increased By 0.04%

May 23, 2018 - By Matthew Harris

Abbott Laboratories (NYSE:ABT) Logo

Bank Of The Ozarks increased Abbott Labs (ABT) stake by 65.82% reported in 2017Q4 SEC filing. Bank Of The Ozarks acquired 10,970 shares as Abbott Labs (ABT)’s stock rose 5.88%. The Bank Of The Ozarks holds 27,637 shares with $1.58M value, up from 16,667 last quarter. Abbott Labs now has $108.44 billion valuation. The stock increased 0.75% or $0.46 during the last trading session, reaching $61.85. About 1.24M shares traded. Abbott Laboratories (NYSE:ABT) has risen 34.85% since May 23, 2017 and is uptrending. It has outperformed by 23.30% the S&P500.

ZARDOYA OTIS ORDINARY SHARES (OTCMKTS:ZRDZF) had an increase of 0.04% in short interest. ZRDZF’s SI was 261,500 shares in May as released by FINRA. Its up 0.04% from 261,400 shares previously. With 100 avg volume, 2615 days are for ZARDOYA OTIS ORDINARY SHARES (OTCMKTS:ZRDZF)’s short sellers to cover ZRDZF’s short positions. It closed at $10.05 lastly. It is down 0.00% since May 23, 2017 and is . It has underperformed by 11.55% the S&P500.

Among 25 analysts covering Abbott Laboratories (NYSE:ABT), 18 have Buy rating, 0 Sell and 7 Hold. Therefore 72% are positive. Abbott Laboratories had 107 analyst reports since July 24, 2015 according to SRatingsIntel. The firm earned “Hold” rating on Thursday, August 31 by BMO Capital Markets. The firm earned “Overweight” rating on Tuesday, January 2 by Morgan Stanley. The firm earned “Buy” rating on Wednesday, June 21 by BTIG Research. The firm earned “Buy” rating on Wednesday, January 24 by Jefferies. RBC Capital Markets maintained it with “Buy” rating and $67.0 target in Wednesday, January 24 report. On Tuesday, September 5 the stock rating was maintained by Jefferies with “Buy”. Barclays Capital maintained the stock with “Overweight” rating in Thursday, January 25 report. On Monday, August 10 the stock rating was reinitiated by Credit Suisse with “Outperform”. Jefferies maintained Abbott Laboratories (NYSE:ABT) on Thursday, July 14 with “Buy” rating. As per Thursday, July 23, the company rating was maintained by Stifel Nicolaus.

Since December 14, 2017, it had 1 insider buy, and 21 selling transactions for $23.88 million activity. PEDERSON MICHAEL J also sold $27,213 worth of Abbott Laboratories (NYSE:ABT) on Friday, February 16. The insider Salvadori Daniel Gesua Sive sold $53,369. On Tuesday, February 27 the insider STARKS DANIEL J bought $2.43 million. Contreras Jaime had sold 6,284 shares worth $375,381. Blaser Brian J sold $1.73M worth of stock. 8,262 shares valued at $518,450 were sold by BIRD ROGER on Friday, March 9. Fussell Stephen R sold 56,401 shares worth $3.36 million.

Investors sentiment increased to 0.91 in Q4 2017. Its up 0.04, from 0.87 in 2017Q3. It increased, as 52 investors sold ABT shares while 558 reduced holdings. 123 funds opened positions while 430 raised stakes. 1.22 billion shares or 0.64% more from 1.21 billion shares in 2017Q3 were reported. 273,695 are held by Stralem Incorporated. 63,695 were reported by Bridges Inv Management Inc. Winch Advisory Ltd Llc accumulated 0.02% or 633 shares. Coe Mngmt Llc invested in 35,282 shares or 2.13% of the stock. Birmingham Mngmt Inc Al holds 32,544 shares. Virginia Retirement Et Al invested in 0.13% or 195,800 shares. Stock Yards Natl Bank Trust owns 235,569 shares. Hl Finance Serv Ltd Liability Corporation accumulated 288,592 shares. Gamble Jones Investment Counsel invested in 282,445 shares or 1.53% of the stock. Cliftonlarsonallen Wealth Lc invested in 0.06% or 10,185 shares. 92,926 were reported by Puzo Michael J. Inv Partners Ltd Oh Adv has invested 0.26% in Abbott Laboratories (NYSE:ABT). Samlyn Capital Lc reported 594,162 shares. Berkshire Asset Management Ltd Liability Pa has 1.5% invested in Abbott Laboratories (NYSE:ABT) for 271,669 shares. First Hawaiian National Bank & Trust has invested 0.1% in Abbott Laboratories (NYSE:ABT).

Abbott Laboratories (NYSE:ABT) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: